Logo image of CERS

CERUS CORP (CERS) Stock Fundamental Analysis

NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD

1.86  +0.06 (+3.33%)

Premarket: 1.88 +0.02 (+1.08%)

Fundamental Rating

2

CERS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. CERS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CERS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CERS had negative earnings in the past year.
In the past year CERS has reported a negative cash flow from operations.
CERS had negative earnings in each of the past 5 years.
In the past 5 years CERS always reported negative operating cash flow.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

CERS's Return On Assets of -10.41% is in line compared to the rest of the industry. CERS outperforms 59.47% of its industry peers.
CERS has a Return On Equity (-36.88%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -10.41%
ROE -36.88%
ROIC N/A
ROA(3y)-20.5%
ROA(5y)-26.31%
ROE(3y)-66.27%
ROE(5y)-76.24%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

CERS's Gross Margin of 60.52% is fine compared to the rest of the industry. CERS outperforms 60.53% of its industry peers.
CERS's Gross Margin has been stable in the last couple of years.
CERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.77%
GM growth 5Y1.4%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CERS has more shares outstanding
The number of shares outstanding for CERS has been increased compared to 5 years ago.
Compared to 1 year ago, CERS has a worse debt to assets ratio.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

CERS has an Altman-Z score of -4.94. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
CERS has a Altman-Z score of -4.94. This is in the lower half of the industry: CERS underperforms 68.42% of its industry peers.
A Debt/Equity ratio of 1.21 is on the high side and indicates that CERS has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.21, CERS is doing worse than 77.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Altman-Z -4.94
ROIC/WACCN/A
WACC9.46%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.59 indicates that CERS has no problem at all paying its short term obligations.
The Current ratio of CERS (2.59) is comparable to the rest of the industry.
CERS has a Quick Ratio of 1.92. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
CERS has a Quick ratio of 1.92. This is comparable to the rest of the industry: CERS outperforms 47.89% of its industry peers.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 1.92
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.69%, which is quite impressive.
The Revenue has been growing slightly by 7.11% in the past year.
The Revenue has been growing by 19.67% on average over the past years. This is quite good.
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)7.11%
Revenue growth 3Y17.82%
Revenue growth 5Y19.67%
Sales Q2Q%15.7%

3.2 Future

The Earnings Per Share is expected to grow by 22.99% on average over the next years. This is a very strong growth
Based on estimates for the next years, CERS will show a quite strong growth in Revenue. The Revenue will grow by 10.20% on average per year.
EPS Next Y40.05%
EPS Next 2Y25.68%
EPS Next 3Y22.99%
EPS Next 5YN/A
Revenue Next Year11.12%
Revenue Next 2Y10.96%
Revenue Next 3Y10.2%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

CERS's earnings are expected to grow with 22.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.68%
EPS Next 3Y22.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CERS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERUS CORP

NASDAQ:CERS (2/4/2025, 8:00:00 PM)

Premarket: 1.88 +0.02 (+1.08%)

1.86

+0.06 (+3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)02-20 2025-02-20/amc
Inst Owners75.96%
Inst Owner Change-0.18%
Ins Owners4.66%
Ins Owner Change-1.39%
Market Cap345.44M
Analysts80
Price Target3.98 (113.98%)
Short Float %4.92%
Short Ratio6.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.56%
Min EPS beat(2)26.47%
Max EPS beat(2)34.64%
EPS beat(4)3
Avg EPS beat(4)28.81%
Min EPS beat(4)-5.03%
Max EPS beat(4)59.15%
EPS beat(8)4
Avg EPS beat(8)8.92%
EPS beat(12)8
Avg EPS beat(12)14.09%
EPS beat(16)10
Avg EPS beat(16)12.32%
Revenue beat(2)0
Avg Revenue beat(2)-3.71%
Min Revenue beat(2)-5.21%
Max Revenue beat(2)-2.21%
Revenue beat(4)0
Avg Revenue beat(4)-5.73%
Min Revenue beat(4)-8.57%
Max Revenue beat(4)-2.21%
Revenue beat(8)1
Avg Revenue beat(8)-5.99%
Revenue beat(12)5
Avg Revenue beat(12)-1.18%
Revenue beat(16)9
Avg Revenue beat(16)1.16%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)12.45%
EPS NQ rev (3m)-366.8%
EPS NY rev (1m)1.46%
EPS NY rev (3m)14.1%
Revenue NQ rev (1m)-5.81%
Revenue NQ rev (3m)-7.08%
Revenue NY rev (1m)-6.24%
Revenue NY rev (3m)2.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.75
P/FCF N/A
P/OCF N/A
P/B 6.46
P/tB 6.62
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.07
BVpS0.29
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.41%
ROE -36.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.52%
FCFM N/A
ROA(3y)-20.5%
ROA(5y)-26.31%
ROE(3y)-66.27%
ROE(5y)-76.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.77%
GM growth 5Y1.4%
F-Score4
Asset Turnover1.04
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.54%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.59
Quick Ratio 1.92
Altman-Z -4.94
F-Score4
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)90.96%
Cap/Depr(5y)139.49%
Cap/Sales(3y)1.36%
Cap/Sales(5y)3.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y40.05%
EPS Next 2Y25.68%
EPS Next 3Y22.99%
EPS Next 5YN/A
Revenue 1Y (TTM)7.11%
Revenue growth 3Y17.82%
Revenue growth 5Y19.67%
Sales Q2Q%15.7%
Revenue Next Year11.12%
Revenue Next 2Y10.96%
Revenue Next 3Y10.2%
Revenue Next 5YN/A
EBIT growth 1Y68.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year123.46%
EBIT Next 3Y37.11%
EBIT Next 5YN/A
FCF growth 1Y59.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.12%
OCF growth 3YN/A
OCF growth 5YN/A